
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Bausch + Lomb Corp (BLCO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $15.14
1 Year Target Price $15.14
3 | Strong Buy |
3 | Buy |
8 | Hold |
1 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.32% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.15B USD | Price to earnings Ratio - | 1Y Target Price 15.14 |
Price to earnings Ratio - | 1Y Target Price 15.14 | ||
Volume (30-day avg) 15 | Beta 0.62 | 52 Weeks Range 10.45 - 21.69 | Updated Date 08/29/2025 |
52 Weeks Range 10.45 - 21.69 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When - | Estimate 0.06 | Actual 0.07 |
Profitability
Profit Margin -5.58% | Operating Margin (TTM) 0.86% |
Management Effectiveness
Return on Assets (TTM) 0.47% | Return on Equity (TTM) -4.02% |
Valuation
Trailing PE - | Forward PE 21.98 | Enterprise Value 9845917911 | Price to Sales(TTM) 1.05 |
Enterprise Value 9845917911 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 2.01 | Enterprise Value to EBITDA 21.69 | Shares Outstanding 353865984 | Shares Floating 42131261 |
Shares Outstanding 353865984 | Shares Floating 42131261 | ||
Percent Insiders 88.07 | Percent Institutions 11.29 |
Upturn AI SWOT
Bausch + Lomb Corp

Company Overview
History and Background
Bausch & Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods store, it grew to become a global leader in eye health products, experiencing significant milestones in lens development, surgical technologies, and consumer eye care. In 2013, it was acquired by Valeant Pharmaceuticals. In 2022, Bausch + Lomb became an independent publicly traded company again.
Core Business Areas
- Vision Care: Contact lenses (daily disposables, reusable, and specialty lenses) and lens care products (solutions and rewetting drops).
- Ophthalmic Pharmaceuticals: Prescription medications for various eye conditions including glaucoma, dry eye, and eye infections.
- Surgical: Surgical instruments, equipment, and consumables for cataract, refractive, and vitreoretinal surgery.
Leadership and Structure
Brent Saunders is the Chairman and CEO. The organizational structure is designed around the three core business areas, with functional departments supporting each segment.
Top Products and Market Share
Key Offerings
- ULTRA Contact Lenses: Monthly replacement contact lenses for astigmatism and presbyopia. Estimated market share in the monthly lens segment is approximately 10%. Competitors include Alcon (AIR OPTIX), CooperVision (Biofinity), and Johnson & Johnson (Acuvue).
- Biotrue ONEday: Daily disposable contact lenses made with a bio-inspired material. Market share is approximately 8% in the daily disposable segment. Competitors include Alcon (DAILIES), CooperVision (MyDay), and Johnson & Johnson (Acuvue).
- Lotemax SM: A corticosteroid ophthalmic suspension used to treat inflammation and pain following ocular surgery. While specific revenue figures are not publicly available, Lotemax SM holds a significant portion of the prescription steroid market. Competitors include Alcon (Lotemax Gel).
- Storz Ophthalmic Instruments: Surgical instrumentation for ophthalmic procedures. They are a leading supplier of surgical products and instruments. Competitors are Alcon, Johnson & Johnson.
Market Dynamics
Industry Overview
The eye health industry is growing, driven by an aging population, increased prevalence of vision problems (e.g., myopia, presbyopia), and technological advancements in eye care products and surgical procedures.
Positioning
Bausch + Lomb is a well-established player in the eye health market, with a broad portfolio of products across vision care, ophthalmic pharmaceuticals, and surgical. Its competitive advantage lies in its strong brand recognition, global presence, and diverse product offering.
Total Addressable Market (TAM)
The global eye care market is projected to reach approximately $200 billion by 2028. Bausch + Lomb is positioned to capture a significant share of this market through its diverse product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Global distribution network
- Diverse product portfolio
- Established relationships with eye care professionals
- Innovation in product development
Weaknesses
- High debt levels (related to its time under Valeant)
- Exposure to generic competition for pharmaceutical products
- Slower growth compared to some competitors in specific segments
Opportunities
- Expanding into emerging markets
- Developing new products and technologies
- Acquiring complementary businesses
- Increasing focus on digital marketing and e-commerce
- Capitalizing on increasing demand for premium eye care products
Threats
- Intense competition from other eye care companies
- Pricing pressure from managed care organizations
- Changes in regulations
- Economic downturns
- Product recalls
Competitors and Market Share
Key Competitors
- ALC
- COO
- JNJ
Competitive Landscape
Bausch + Lomb competes with several large and well-established companies. Its advantages include a broad product portfolio and global presence. Disadvantages include high debt levels and slower growth in some segments compared to its peers. They are focused on innovation to maintain a strong presence within the industry.
Major Acquisitions
Acquired Company Name
- Year: 2024
- Acquisition Price (USD millions): 125
- Strategic Rationale: To expand their current eye health segment to the Chinese market and increase company revenue.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been steady, driven by new product launches and geographic expansion.
Future Projections: Analysts project revenue growth of 4-6% per year over the next 3-5 years, driven by continued demand for eye care products and surgical procedures.
Recent Initiatives: Recent initiatives include expanding its presence in China, launching new contact lens products, and investing in research and development.
Summary
Bausch + Lomb is a strong global player in the eye health market with a diverse portfolio and established brand. Its high debt and competitive environment present challenges. Its strengths in branding, global distribution, and product innovation drive growth. They need to focus on debt reduction and leveraging market opportunities to enhance their competitive positioning.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch + Lomb Corp
Exchange NYSE | Headquaters Vaughan, ON, Canada | ||
IPO Launch date 2022-05-06 | CEO & Chairman Mr. Brenton L. Saunders J.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.bausch.com |
Full time employees 13500 | Website https://www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.